The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | Epcoritamab versus mosunetuzumab in patients with R/R FL: findings of a MAIC
Alexey Danilov, MD, PhD, City of Hope, Duarte, CA, outlines the findings of a matching-adjusted indirect comparison (MAIC) of bispecific antibodies epcoritamab and mosunetuzumab for the treatment of patients with relapsed/refractory (R/R) follicular lymphoma (FL). The efficacy and safety of the two agents were comparable; however, Prof. Danilov highlights that numerically, epcoritamab resulted in a higher response rate with slightly fewer cases of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
A number of Bispecifics are currently in development for the treatment of follicular lymphoma, diffuse large B-cell lymphoma, as well as other lymphomas, and mosunetuzumab was approved in treatment of follicular lymphoma, and several of these bispecific antibodies have been studied in Phase II clinical trials. But there are no currently ongoing clinical trials that I’m aware of that are comparing these bispecific antibodies to one another...
A number of Bispecifics are currently in development for the treatment of follicular lymphoma, diffuse large B-cell lymphoma, as well as other lymphomas, and mosunetuzumab was approved in treatment of follicular lymphoma, and several of these bispecific antibodies have been studied in Phase II clinical trials. But there are no currently ongoing clinical trials that I’m aware of that are comparing these bispecific antibodies to one another.
So we conducted a MAIC or matching-adjusted indirect comparison of clinical trials where patients were enrolled on different bispecific antibodies, and specifically we compared epcoritamab and mosunetuzumab. And we found that both antibodies were of course highly efficacious, comparable in their efficacy, numerically epcoritamab was associated with a somewhat higher response rate. What’s also important to note is that those studies ran in slightly different eras where there were more Covid events on the epcoritamab study compared with mosunetuzumab study.
Also, patients enrolled on the epcoritamab study were slightly more heavily pretreated, they had more cases of prior autologous stem cell transplant, but nevertheless, progression-free survival was comparable between epcoritamab treated patients and mosunetuzumab treatment patients. And in terms of safety, it was good for both drugs. However, there were slightly fewer cases of CRS and neurotoxicity with epcoritamab compared with mosunetuzumab.
So in sum, both bispecific antibodies are highly efficacious in the treatment of relapsed refractory follicular lymphoma. Numerically higher responses with epcoritamab and maybe slightly better safety compared with mosunetuzumab.
Read more...
